Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nature reviews. Cancer, 2002 May, 2(5): 389-96. doi:10.1038/nrc801. PMID 12044015..
DOI: 10.1038/nrc801. PMID 12044015
Gao W. Androgen receptor as a therapeutic target. Advanced drug delivery reviews, 2010, 62(13): 1277-84. doi:10.1016/j. addr.2010.08.002. PMID 20708648..
DOI: 10.1016/j. addr.2010.08.002. PMID 20708648
Singh SM, Gauthier S, Labrie F. Androgen receptor antagonists (antiandrogens): structure-activity relationships. Current medicinal chemistry, 2000 Feb, 7(2): 211-47. doi:10.2174/0929867003375371. PMID 10637363..
DOI: 10.2174/0929867003375371. PMID 10637363
Williams L, Thompson LD, Seethala RR, Weinreb I, Assaad AM, Tuluc M, Ud Din N, Purgina B, Lai C, Griffith CC, Chiosea SI. Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression. The American journal of surgical pathology, 2015 May, 39(5): 70513. doi:10.1097/ pas.0000000000000413. PMID 25871467..
DOI: 10.1097/ pas.0000000000000413. PMID 25871467
Haendler B, Cleve A. Recent developments in antiandrogens and selective androgen receptor modulators. Molecular and cellular endocrinology, 2011, 352(1–2): 79-91. doi:10.1016/j. mce.2011.06.002. PMID 21704118..
DOI: 10.1016/j. mce.2011.06.002. PMID 21704118
Gao W. Peptide antagonist of the androgen receptor. Current pharmaceutical design, 2010, 16(9): 1106-13. doi:10.2174/138161210790963850. PMID 20030610..
DOI: 10.2174/138161210790963850. PMID 20030610
Gao W, Kim J, Dalton JT. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharmaceutical Research, 2006 Aug, 23(8): 1641-58. doi:10.1007/s11095- 006-9024-3. PMC 2072875. PMID 16841196..
DOI: 10.1007/s11095- 006-9024-3. PMC 2072875. PMID 16841196
Kasper P. Cyproterone acetate, a genotoxic carcinogen? Pharmacol. Toxicol., 2001, 88: 223-231.
Eisenberg MA, Blumenstein BA, Crauford ED et.al. Bilateral orchectomy with or without flutamide for metastatic prostate cancer. N. Eng. J. Med., 1998, 98: 1036-1042.
Dijukman GA, Janket RA, De Reijke TM et.al. Long-term efficacy end safety jf nilutamide plas castration in advansed prostate cancer and significance of early prostatic antigen normalizatium. J Urology, 1997, 158: 160-163.
Iversen P, Tyrrel Cj, Kaisary A et al. Bicalutamide monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer, 6,3 years of follow up. J Urol, 2000 Nov, 164(5): 1579-82.
Рак предстательной железы. Под ред. Н.Е. Кушлинского, Ю.Н. Соловьева, М.Ф. Трапезниковой. М., 2002, С. 427. 12. / Prostate gland cancer. Ed. by N.E. Kushlinsky, Y.N. Soloviev, M.F. Trapeznikova. M., 2002, p. 427.
Kim TH, Jeong JW, Song JH, Lee KR, Ahn S, Ahn SH, Kim S, Koo TS. Pharmacokinetics of Enzalutamide, an Anti-prostate Cancer Drug, in rats. Archives of Pharmacal Research, 2015 Nov, 38(11): 2076-82. PMID 25956695.
Medivation’s MDV3100 Shown to Be Effective in a Preclinical Model of Hormone- Refractory Prostate Cancer. Press release. Medivation, Inc. 2007-02-26. Retrieved 2009-05- 10.
FDA approves new treatment for a type of late stage prostate cancer. Press release. United States Food and Drug Administration. 2012-08-31.
Azvolinsky A. FDA Approves Enzalutamide (Xtandi) for Late-Stage Prostate Cancer. Cancer Network, 2012 September, 4.
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V et al. Development of a second- Generation antiandrogen for treatment of advanced prostate cancer. Science, 2009 May, 324(5928): 787-90. doi:10.1126/science. 1168175. PMC 2981508. PMID 19359544..
DOI: 10.1126/science. 1168175. PMC 2981508. PMID 19359544
Rodriguez-Vida A, Chowdhury S, Sternberg C, Rudman S, Galazi M. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Drug Design, Development and Therapy, 2015, 9: 3325-39. doi:10.2147/DDDT.S69433. ISSN 1177-8881. PMID 26170619..
DOI: 10.2147/DDDT.S69433. ISSN 1177-8881. PMID 26170619
Antonarakis ES. Enzalutamide: The emperor of all anti-androgens. Transl Androl Urol, 2013, 2(2): 119-120. PMC 3785324. PMID 24076589. NCT01288911. ClinicalTrials.gov, United States National Institutes of Health. Retrieved 2011- 11-06. A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer.
NCT01288911. ClinicalTrials.gov, United States National Institutes of Health. Retrieved 2011- 11-06. A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer.
NCT00974311. ClinicalTrials.gov, United States National Institutes of Health. Retrieved 2009-10-29. Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM).
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med., September 2012, 367(13): 1187-97. doi:10.1056/NEJMoa1207506. PMID 22894553..
DOI: 10.1056/NEJMoa1207506. PMID 22894553
ClinicalTrials.gov, United States National Institutes of Health. Retrieved 2011-11-06. A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL). NCT01212991.
Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, van Os S, Hasabou N, Wang F, Bhattacharya S, Heidenreich A, Phung. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, oubleblind, phase 2 study. Lancet Oncology, 2016, 17(2): 153-163.